Effect of S-1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7-year multicenter observational cohort study in Taiwan.

Authors:
Hsiang-Lan Lai
Hsiang-Lan Lai
Chang Gung Memorial Hospital at Kaohsiung
Jen-Shi Chen
Jen-Shi Chen
Chang Gung Memorial Hospital
Taiwan

Cancer Med 2019 Apr 18. Epub 2019 Apr 18.

Division of Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.

Objective: Studies have rarely explored the efficacy of S-1 in treating advanced pancreatic cancer outside Japan. This study compared the survival outcomes of patients with advanced pancreatic cancer treated with S-1 with the survival outcomes of those without S-1 treatment before and after S-1 reimbursement was introduced in Taiwan in June of 2014.

Method: We retrospectively analyzed 838 patients with locally advanced or metastatic pancreatic cancer who underwent palliative chemotherapy from 2010 to 2016 at 4 institutes in Taiwan. For survival analysis, patients were categorized into two groups according to whether they received S-1 treatment as palliative chemotherapy after diagnosis: (a) S-1-treated (n = 335) and (b) non-S-1-treated (n = 503) groups.

Results: The median overall survival was longer in the S-1-treated group than in the non-S-1-treated group (10.7 vs 6.0 mo, P < 0.001). Subgroup survival analyses showed that the S-1-treated group had more favorable outcomes than the non-S-1-treated group in terms of stage III (19.6 vs 10.1 mo, P < 0.001) and stage IV (8.5 vs 5.3 mo, P < 0.001) disease. The disease control rates were 43.6% and 32.8% (P < 0.001) in patients treated with and without S-1 in the first-line setting, respectively. In multivariate analysis, exposure to S-1 treatment was an independent prognosticator for survival.

Conclusion: Our results support the clinical use of S-1 as the treatment of choice for patients with locally advanced or metastatic pancreatic cancer, particularly in resource-limited situations.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2094DOI Listing
April 2019

Publication Analysis

Top Keywords

pancreatic cancer
16
advanced pancreatic
12
survival outcomes
12
patients advanced
8
palliative chemotherapy
8
s-1 treatment
8
838 patients
8
s-1 survival
8
s-1
6
n = 335 non-s-1-treated
4
june 2014method
4
analyzed 838
4
2014method retrospectively
4
retrospectively analyzed
4
non-s-1-treated n = 503
4
taiwan june
4
s-1 reimbursement
4
treated s-1
4
cancer treated
4
groups received
4

References

(Supplied by CrossRef)
Cancer statistics, 2019
Siegel RL et al.
CA Cancer J Clin 2019
Resection versus other treatments for locally advanced pancreatic cancer
Gurusamy KS et al.
Cochrane Database Syst Rev 2014
Epidemiology of pancreatic cancer
Ilic M et al.
World J Gastroenterol 2016
Pancreatic cancer epidemiology and survival in an Australian population
Luke C et al.
Asian Pac J Cancer Prev 2009
Pancreatic cancer epidemiology, detection, and management
Zhang Q et al.
Gastroenterol Res Pract 2016

Similar Publications